Kornimate/medical-research-clean huggingface dataset:
psychological and enterostomal therapy care

Conditions: Cancer of Rectum

Summary: in case of rectal cancer surgery, temporary stoma is recommended to decrease the risk of postoperative anastomotic leakage. the aim of the study was to assess the benefit of an optimal care, i.e., both psychological and enterostomal therapy care.

the aim of the study is to asses the benefit of an optimal and specific care concerning the temporary stoma in patients operated for rectal cancer surgery in term of psychological and enterostomal therapy effect. this study is a monocentric and randomized trial.

Eligibility criteria:
inclusion criteria: * age \> 18 y * rectal adenocarcinoma (tumor height \< 15 cm from the anal verge) with or without pre operative radiochemotherapy. * open or laparoscopic rectal excision with partial or total meso rectal excision with sphincter preservation by colo rectal or colo anal anastomosis. * temporary stoma. * patient consent * patient with national health affiliation exclusion criteria: * stage iv disease with synchronous hepatic or pulmonary metastases * colonic cancer \> 16 cm * associated surgical procedure (hepatic resection, small bowel resection subtotal colectomy) * abdominal perineal resection * associated comorbidity * emergency surgery * psychological care refusal

Keywords: rectal cancer temporary stoma psychological disorders
aerobic vs core stability exercise training program in women with endometriosis

Conditions: Endometriosis

Summary: to compare the effects of aerobic and core stability exercise training program on pain, sleep and quality of life in women with endometriosis.


Eligibility criteria:
inclusion criteria: * age 24-45 * diagnosed patients with endometriosis * pain lasting more than 6 months * chronic pelvic pain * infertility * patients with dysmenorrhea. exclusion criteria: * patients with the tubo- ovarian abscess. * concomitment use of hormonal drugs. * any malignancy * impaired sensation.. * patients with gynecological hemorrhage

Keywords: endometriosis aerobic exercises, core stability, quality of life
study of ds-5141b in patients with duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: this is a phase i/ii study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (pk) profile of ds-5141b in patients with duchenne muscular dystrophy (dmd) amenable to exon 45 skipping and to determine the dosage for subsequent studies.


Eligibility criteria:
inclusion criteria: * confirmation of out-of-frame deletion(s) that could be corrected by dystrophin gene exon 45 skipping. * intact muscles of adequate quality for biopsy to allow evaluation of the efficacy of the study drug. * boys aged from 5 years to \<11 years. * patients able to walk at least 325 meters in the 6-minutes walk test. * glucocorticoid-naive patients, or patients who have used glucocorticoids for at least 6 months prior to enrollment in this study with no dose changes for at least 3 months prior to enrollment. exclusion criteria: * a genetic mutation that can not be expected the expression of dystrophin protein by dystrophin gene exon 45 skipping. * a concurrent illness other than dmd that can cause muscle weakness and/or impairment of motor function. * current or history of severe disorder. * left ventricular ejection fraction (levf) \<55%. * corrected qt interval (qtc) \>0.45 sec.

Keywords: duchenne muscular dystrophy dmd oligonucleotides, antisense exon skipping
investigation of relation with preoperative fragility and asa score in elderly patients

Conditions: Frail Elderly Syndrome; Muscle Weakness

Summary: frailty is a term specific to the geriatric period. it is used to describe weak, unstable, frail patients and partially expresses the frailty of the elderly patient. once the frailty process begins, the risk of loss of mobility, dependency and mortality increases. frailty is an important predictor of adverse outcomes after surgery. according to studies conducted in various surgical situations, fragility is a major risk factor for morbidity, mortality and longer hospital stay. according to the available data, frailty has a sufficient basis for determining the risks of patients before surgery, developing preventive methods and making personal treatment decisions. as the frailty index increased, it was observed that the duration of postoperative hospital stay was associated with the need for intensive care, postoperative complications, and the rate of re-admissions within 30 days. asa (american society of anesthesiologists) classification is widely used in order to evaluate the physical condition preoperatively in geriatric individuals with multiple comorbidities. considering the fragility variable while creating the asa score in the preoperative period may be useful in determining the follow-up strategy during the operation and postoperative period. for example, a patient who is evaluated as asa 2 because he has no problems other than simple 1-2 comorbid conditions, involuntary weakening of 5% in the last 1 year (not easily noticed), weakness (can only be detected with a dynamometer) and cessation of going out of the house (can only be understood when asked privately). ) can be categorized as at risk at asa level 3-4, as it is understood to be fragile. the aim of this project is to examine the frequency of frailty in elderly individuals who will be operated on, and to examine the relationship between frailty and asa score using the anthropometry and comorbidity differences between frail preoperative patients and those who do not.


Eligibility criteria:
inclusion criteria: - patients over the age of 65 who were admitted to the general surgery service for surgery and then operated. exclusion criteria: -patients with advanced stage dementia
pdd vs pad to treat initially diagnosed mm

Conditions: Multiple Myeloma

Summary: the purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.


Eligibility criteria:
inclusion criteria: * newly diagnosed and untreated multiple myeloma patients * patients with age between 18 and 70 years * with a evaluable disease * ecog score ≤2 * ne≥1.0×10e9 /l, plt≥50×10e9 /l, hb≥70 g/l * ast, alt, alp≤3×uln, serum bil≤uln * lvef≥ 50% * not in pregnancy * written informed consent are acquired exclusion criteria: * severe heart failure (nyha grade ii or higher) * active and uncontrolled severe infection * hiv positive * have accepted any other anti-tumor drug within 30 days before the first dose of doxorubicin hydrochloride iposome or doxorubicin * grade 2 or higher peripheral neuropathy before treatment * have suffered any other malignancy in past 5 years * females in lactation * other situations that investigators consider as contra-indication for this study

Keywords: doxorubicin hydrochloride
hospital-level variation in the management of blood pressure and low-density lipoprotein in the outpatient hypertensives in china-a cross sectional study

Conditions: Hypertension; Hyperlipidemia

Summary: to investigate the proportion, medication use and control rate of metabolic abnormalities such as dyslipidemia in outpatients with hypertension in different levels of hospitals in china. to investigate the gap between guidelines and clinical practices, and analyze the cause. we also set up a continuing medical education program to narrow the gap and the effect of the program will be estimated.


Eligibility criteria:
inclusion criteria: 1. outpatients from departments of cardiology, endocrinology, nephrology, neurology, geriatrics or general internal medicine. 2. diagnosed as hypertension. diagnostic criteria: 1)the office bp measured at the day of visit and at least one time before that day were above the cut-off values ( ≥140 mmhg sbp and/or ≥90 mmhg dbp); 2)for patients with normal bp at the day of visit, they should have already been given pre-treatment with antihypertensive drugs ≥ 2 weeks. 3. voluntary participation. exclusion criteria: 1. patients aged\< 18 years old. 2. patients without a definite diagnosis of hypertension（for instance, if the patient has been taking antihypertensive drugs irregularly, it is difficult to confirm the diagnosis of hypertension）. 3. patients with a definite diagnosis of secondary hypertension. 4. patients are diagnosed dyslipidemia with clear cause, such as nephrotic syndrome, severe hypothyroidism, terminal stage of malignancy, etc. 5. patients are diagnosed end-stage renal disease, hemodialysis, and peritoneal dialysis patients. 6. patients diagnosed with mental abnormalities who are unable to complete the questionnaire. 7. patients have once participated in this research during this study cycle（to avoid repeated participation）.
nudging flu vaccination in patients at moderately high risk for flu and flu-related complications

Conditions: Influenza; Vaccination; Health Promotion; Health Behavior; Risk Reduction

Summary: this study will test the relative efficacy of high-risk messages in increasing flu shot rates in patients at moderately high risk for flu and complications (those in the top 11-20% of risk). it will also examine whether informing patients that their high-risk status was determined by analyzing their medical records or by an artificial intelligence (ai) / machine-learning (ml) algorithm analyzing their medical records will affect the likelihood of receiving a flu vaccine.

almost everyone age 6 months or older can benefit from the vaccine, which can reduce illnesses, missed work, hospitalizations, and death by reducing the likelihood of contracting influenza. flu shots are particularly important for patients at high risk of experiencing severe outcomes. in the 2020-21 and 2021-22 flu seasons, the study team sent messages to geisinger patients in the top 10% of risk for flu and complications according to an artificial intelligence algorithm. messages that disclosed patients' risk status significantly increased flu vaccination rates. additionally, messages that included risk information were most effective in patients at relatively lower risk (those in the top 4-10%) compared with those at the highest risk (top 3%). the present work will test the effectiveness of high-risk messages in patients who are in the top 11-20% of risk, at high risk but lower than previous studies. these communications will inform patients they are at high risk with either (a) no additional explanation, (b) an explanation that this determination comes from an analysis of their medical records, or (c) the additional explanation that an ai or ml algorithm made this determination.

Eligibility criteria:
inclusion criteria: * included on a list of active geisinger patients (all patients on this list attended at least one primary care appointment at geisinger between 10/1/2008 and 4/13/2022, and either had a geisinger primary care provider assigned as of april 2022, or were in the electronic health record \[ehr\] since at least september 2021 and had at least one encounter in 2020-2022) * aged 18 or older * in the top 11-20% of risk for flu and flu complications, according to medial's flu complications machine learning algorithm (which operates on coded ehr data) * has a geisinger pcp assigned as of august 2022 * has had an encounter in the last 2 years as of august 2022 exclusion criteria: - cannot be contacted via any of the communication modalities (e.g., letter, patient portal, sms) being used in the study, either due to insufficient/missing contact information in the ehr or because they opted out of all modalities

Keywords: flu vaccine choice architecture machine learning perceived credibility
magnet resonance imaging to evaluate of dynamic t2 preparation puls by patients with shunt or chronic obstructive pulmonary disease

Conditions: Dynamic T2 Preparation

Summary: there is preliminary evidence that a dynamic t2 preparations puls sequence by cardiac magnet resonance imaging can differentiate between oxygenated and deoxygenated blood. in adult patients with inborn heart defects this has not yet been researched. therefore,patients with ventriculoperitoneal shunt, septal and atrio-septal shunt should be examined. also, patients with chronic obstructive pulmonary disease should be examined. the aim of this study is the validation of a novel magnet resonance sequence in terms of a distinction of oxygenated blood to deoxygenated blood in comparison to invasive method of measuring cardiac catheterization.


Eligibility criteria:
inclusion criteria: * patients with atrial septal defect (asd) or ventricular septal defect (vsd) and copd * written informed consent exclusion criteria: * patients with st-elevation * contraindication for mri * heavy kidney disease * pregnant or breast feeding women

Keywords: mri shunt copd dynamic t2 preparation puls new sequences magnet resonance imaging ventricular septal defect atrial septal defect
study of lx3305 in subjects with active rheumatoid arthritis on stable methotrexate

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to evaluate the safety, tolerability, and effectiveness of lx3305 versus a placebo control in subjects with active rheumatoid arthritis on stable methotrexate therapy.


Eligibility criteria:
inclusion criteria: * males and females aged 18-75 years old * rheumatoid arthritis present for at least 6 months, functional class i, ii, or iii as defined by acr criteria * active disease as determined by the presence of ≥6 swollen joints, ≥6 tender joints, and serum c-reactive protein level \> upper limit of normal * receiving stable dose of mtx (≥10 mg/wk) and folate supplementation at least 8 weeks prior to day 1 * ability to provide written informed consent exclusion criteria: * ra diagnosis prior to 16 years of age (juvenile ra) * lack of response to \>3 disease modifying anti-rheumatic drugs (dmards) or exposure to \>1 biologic dmard * use of dmards other than mtx within 12 weeks prior to day 1 * intra-articular and/or parenteral corticosteroids within 4 weeks prior to study day 1 * blood donation or receipt of live vaccine within 4 weeks prior to day 1 * major surgical procedure within 8 weeks prior to day 1 * any systemic inflammatory condition, recurrent infection, or current infection other than onychomycosis * history of cancer within 5 years prior to day 1 * presence of hepatic or biliary disease * history of tuberculosis * history of human immunodeficiency virus (hiv)
3-month home-based training with whole body vibration device in patients with pah (galileo-pah-home)

Conditions: Changes in Six Minute Walking Distance, Peak Oxygen Uptake, Quality of Life

Summary: in order to evaluate long term effects of whole body vibration (wbv) in patients with pah and cteph patients will get a training device to use at home for 3 months. patients in the intervention group will be introduced in the training program on the wbv-device in the study center 3-4 times and baseline parameters will be collected before start of the home based training. patients randomized into the placebo arm be introduced into the training program according to the interventional arm but not perfoming the exercises on the wbv-device but on the floor.

screening (day -21 until day -7): subjects will be evaluated according to in- and exclusion critera randomization (day -7): subjects will be randomized to either intervention group (training on wbv platform) or non-intervention group (training without wbv). introduction week -1(-7d-d1): all subjects will receive introduction in their training month 1: day 1: from this day subjects are supposed to start their training accoridng to protocol day 2: telephone visit day 5: telephone visit day 7: telephone visit day 10: telephone visit day 13: telephone visit day 20: telephone visit day 27: telephone visit week 4, day 28: study center visit: 6mwd, qol-questionnaire, aes, re-training month 2: week 5, day 34: week 6, day 41: week 7, day 48: week 8, day 55: month 3: week 9, day 62: week 10, day 69: week 11, day 76: week 12, day 83: final visit

Eligibility criteria:
inclusion criteria: * men and women age 18-90 years * signed informed consent * symptomatic pah (idiopathic, hereditary or associated with systemic scleroderma) * persistend or inoperable cteph * invasively confirmed pah * 6mwt ≥ 50 - 450 m * stable specific therapy for at least 6 weeks * ability to perform bike test * ability to perform wbv training * nyha/who-fc ii-iii exclusion criteria: any other pah/ph than idiopathic, hereditary, associated with systemic scleroderma or cteph * rehabilitation or other training concept performed within 6 weeks before inclusion * pregnancy * acute thrombosis * newly implanted hip or knee * recent bone fracture * disability to confirm consent * nyha/who-fc iv * 6mwd below 50 or above 450 m
autoimmune phenomena after acute stroke

Conditions: Stroke

Summary: the damage of the brain parenchyma, as well as the stroke-induced dysfunction of the blood-brain-barrier can make previously hidden cns antigens "visible", and can thus lead to the development of autoimmune mechanisms. it seems plausible that stroke-associated immunodepression influences the development and the phenotype of these autoreactive immune responses. this study will investigate whether cerebral ischemia leads to changes in the immune response, in particular to the development and/or proliferation of autoreactive effector t-cells and/or regulatory t-cells. furthermore, the association between the severity and the phenotype of this autoimmune response and the clinical course, i.e. prognosis and mortality, will be investigated.


Eligibility criteria:
inclusion criteria: * acute media infarct or intracerebral bleeding within the last 36 h (patients) * nihss \> 7 (patients) * age \> 17 years (patients), age \> 54 years (controls) * informed consent of patient or legal representative/ of control * cardiovascular risk such as diabetes mellitus (control) exclusion criteria: * infections (patients, controls) * antibiotic or immunosuppressive treatment within the last 4 weeks (patients) * other cns disorders

Keywords: stroke-induced immunodepression acute media infarct acute intracerebral bleeding leucocytes autoaggressive t-cells acute media infarct or acute intracerebral bleeding
improving nighttime access to care and treatment; part 2- ghana

Conditions: Pediatric ALL; Acute Disease

Summary: globally, leading causes of death among children one month to 5 years old are pneumonia, diarrheal disease and malaria which are treatable early in the disease-course with low-cost medications. however, these diseases can progress to emergencies when access to care is delayed. in response, a telemedicine and medication delivery service (tmds) was designed to improve nighttime access to pediatric care and treatment. the tmds will be implemented in three distinct ghanaian community to evaluate the clinical safety, operational feasibility of implementing,and scalability of the service.

globally, leading causes of death among children one month to 5 years old are pneumonia, diarrheal disease and malaria which are treatable early in the disease-course with low-cost medications. however, these diseases can progress to emergencies when access to care is delayed. in response, a telemedicine and medication delivery service (tmds) called motomeds was designed to overcome barriers to seeking care. motomeds targets the nighttime period when barriers to accessing care are highest. the tmds was initially deployed in haiti and will now be evaluated for generalizability and portability in ghana. the study objectives are to assess clinical safety and logistical feasibility of the tmds. the study population is children in accra and tamale. the workflow consists of parents/guardians calling the tmds on their child's behalf, emergency medical technicians (emts) referring severe cases to emergency services, emts performing a phone assessment for non-severe cases, and emts traveling to the child's household to perform an in-person exam, rapid diagnostic testing for malaria where indicated as per protocol, and to deliver protocolized medications for cases within a predefined delivery zone. emts and the protocols/guidelines used are supervised by ghanaian and us physicians. clinical safety and feasibility of the tmds will be evaluated using patient and logistical metrics.

Eligibility criteria:
child participant inclusion criteria: * child ≤ 10 years * has an acute medical problem * provides written assent (if 10 years and receives a household visit) child participant exclusion criteria: * child \> 10 years * child does not have an acute medical problem * medical problem involves physical trauma or mental health * refusal of written assent (if 10 years and receives a household visit) parent/guardian participant inclusion criteria: * calls motomeds during operating hours * parent/guardian of a patient participant meeting inclusion criteria * adult (18 years or older) * provides written consent (household visit) or a waiver of documentation of consent (no household visit) parent/guardian participant exclusion criteria: * age \< 18 years * no written consent or waiver of documentation of consent * corresponding child does not meet inclusion criteria

Keywords: telemedicine healthcare access nighttime
second phase of the pilot study for obtaining mature oocytes by in vitro maturation in oocyte-donor women

Conditions: Infertility, Female; Oocyte Maturation

Summary: in vitro maturation (ivm) is a technique for obtaining potentially fertilizable oocytes from immature oocytes. an oocyte must be mature both nuclearly and cytoplasmically in order to be competent in the reproductive process. nuclear maturation involves an oocyte in metaphase ii stage and is easily evaluated for its morphology. however, cytoplasmic maturation can only be evaluated by in vitro fertilization of that oocyte. a mature nuclear and cytoplasmic oocyte is the one capable of producing a viable embryo. this study aims to optimize the in vitro maturation (ivm) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase ii stage. in addition, an artificial oocyte activation (aoa) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos. this study corresponds to a second phase of the pilot study for the development of this technique in our ivf laboratory. we will use all we have learned in the first phase, as well as the experience acquired, to advance in the optimization of this protocol. the correct functioning of this ivm technique would mean a reduction in the costs of ovarian stimulation treatments, as lower doses and shorter stimulation times are required, which implies lower risks for women derived from the medication and less stress for them.


Eligibility criteria:
-inclusion criteria: women between 18-35 years old who have belonged to the egg donation program. donors who agree to participate in the study after informing and signing the informed consent. documented previous good response to ovarian stimulation (at least 10 total oocytes and/or 8 mii). donors with at least one previous donation cycle, in which all oocytes obtained were freshly fertilized. donors who have already done all their donation cycles allowed by law. no personal or family history of interest. from the medical point of view: body mass index between 18-25 kg/m2. normal uterus and ovaries, without organic pathology. no polycystic ovaries antral follicle count (afc) \>12 in the sum of the two ovaries on day 2-3 of the menstrual cycle. normal karyotype negative screening for infectious diseases (hepatitis b virus, hepatitis c virus, human immunodeficiency virus and syphilis). general analysis with hemogram, hemostasis and biochemistry with parameters within normality. -exclusion criteria: any systemic or metabolic disorder that contraindicates the use of gonadotropins. any medical condition that implies non-inclusion in the oocyte donation program. taking hormonal contraceptives within the last 3 months.

Keywords: in vitro maturation oocyte activation follicular puncture hmg-hp oocyte donnors